Pegylated Interferon Alfa 2a and Small Dose Ribavirin in The Treatment of HCV Genotype 4 in End-stage Renal Disease
Shendy, S., AlAnsary, M., Saleem, A., El-Talkawy, M., AbdelAziz, A., Raafat, M., Nabil, M. (2014). Pegylated Interferon Alfa 2a and Small Dose Ribavirin in The Treatment of HCV Genotype 4 in End-stage Renal Disease. EKB Journal Management System, 57(1), 450-459. doi: 10.12816/0008480
Shendy Mohammed Shendy; Mahmoud AlAnsary; Abdel Aziz Ali Saleem; Mohamed Darwish El-Talkawy; Ayman AbdelAziz; Manar Raafat; Malak Nabil. "Pegylated Interferon Alfa 2a and Small Dose Ribavirin in The Treatment of HCV Genotype 4 in End-stage Renal Disease". EKB Journal Management System, 57, 1, 2014, 450-459. doi: 10.12816/0008480
Shendy, S., AlAnsary, M., Saleem, A., El-Talkawy, M., AbdelAziz, A., Raafat, M., Nabil, M. (2014). 'Pegylated Interferon Alfa 2a and Small Dose Ribavirin in The Treatment of HCV Genotype 4 in End-stage Renal Disease', EKB Journal Management System, 57(1), pp. 450-459. doi: 10.12816/0008480
Shendy, S., AlAnsary, M., Saleem, A., El-Talkawy, M., AbdelAziz, A., Raafat, M., Nabil, M. Pegylated Interferon Alfa 2a and Small Dose Ribavirin in The Treatment of HCV Genotype 4 in End-stage Renal Disease. EKB Journal Management System, 2014; 57(1): 450-459. doi: 10.12816/0008480

Pegylated Interferon Alfa 2a and Small Dose Ribavirin in The Treatment of HCV Genotype 4 in End-stage Renal Disease

The Egyptian Journal of Hospital Medicine
Article 9, Volume 57, Issue 1, October 2014, Page 450-459  XML PDF (289.77 K)
Document Type: Original Article
DOI: 10.12816/0008480
View on SCiNiTO View on SCiNiTO
Authors
Shendy Mohammed Shendy1; Mahmoud AlAnsary1; Abdel Aziz Ali Saleem1; Mohamed Darwish El-Talkawy1; Ayman AbdelAziz1; Manar Raafat2; Malak Nabil2
1Hepatogastroenterology department Theodor Bilharz Research institute, Giza, Egypt.
2Nephrology department,Theodor Bilharz Research institute, Giza, Egypt.
Abstract
Background:As hepatitis C virus (HCV) infection is a major health problem in patients with end-stage renal disease (ESRD).
Aim:explore the response rate and adverse effects of pegylated interferon and ribavirin in treating HCV genotype 4 in patients withend stage renal disease (ESRD) waiting renal transplantation.
Patients &Methods:This study included 24 patients with ESRD and active HCV infection as detected by clinical, sonographic, biochemical, serological, virological and histological examination with liver biopsy. All patients were under hemodialysis with HCV antibodies positive > 6 months.  Viral genotyping and both qualitative and quantitative PCR were carried out before starting therapy. Treatment was continued for 48 weeks using pegasys 135 µg weekly and ribavirin 200 mg daily. The biochemical and virological responses were evaluated regularly during and after treatment. The sustained virological response (SVR) being evaluated 24 weeks later. The side effects were monitored throughout the treatment period.
Results:Rapid virological response (RVR) after week 4 was achieved in 11/24 (46%) patients. The sustained virological response (SVR) was achieved in 16/24 (66.7%) patients. No break through or relapses were detected during and after treatment respectively. Correlation was found between the viral load before treatment and that at week 4 with p < 0.001and at 12 weekand between the reduction of hemoglobin and the reduction of viral load at week 12 with p < 0.045.
Conclusion:genotype 4 HCV patients with ESRD can be considered for therapy pre-operatively to overcome all the morbidities associated with persistence of HCV after renal transplantation provided that the general condition, the hematological parameters and all other factors of treatment allowed such therapy.
 
 
Keywords
Pegylated Interferon alfa 2a; Ribavirin; HCV genotype 4; End-stage renal disease
Statistics
Article View: 114
PDF Download: 196